Diabetes management company Glooko is partnering with Copenhagen-based Hedia to integrate its app into Glooko’s remote monitoring platform.
The Hedia Diabetes Assistant allows patients to input their blood glucose, meals and activity levels and provides bolus insulin dosing recommendations. Under the partnership, the app will integrate with Glooko’s platform, which lets patients share diabetes data with their providers, including blood glucose, insulin doses, food and carbs, exercise, blood pressure, and weight.
In the European Union, patients can also use the app with connected insulin pens. Glooko said using the functionality would give providers more insight into their patients’ insulin therapy.
The companies expect to launch the integration in Europe in the fourth quarter this year and the first quarter of 2024.
“We are very pleased to partner with Hedia to offer this algorithm-driven innovation for personalized healthcare for diabetes patients and their healthcare teams,” Russ Johannesson, CEO of Glooko, said in a statement.
“The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps. This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.”
THE LARGER TREND
The digital health startup also acquired two fellow diabetes-focused companies last year. In January 2022, it announced it had purchased Berlin-based xbird, maker of AI-based diabetes care tools.
In March last year, Glooko acquired Paris-based DIABNEXT, another diabetes care platform.
Evelyn Gallego will offer more detail in the HIMSS23 session “Data for Health Equity: Improving Maternal Health Outcomes Through Interoperability.” It is scheduled for Wednesday, April 19 at 2:30 p.m. – 3:30 p.m. CT at the South Building, Level 1, S105A.